35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin

Last updated: May 18, 2024
Sponsor: Nakhia Impex LLC
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hives (Urticaria)

Rash

Allergy

Treatment

35 kDa hyaluronan fragment HA35 injection

Clinical Study ID

NCT06387212
HUI0001
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Skin problems include but are not limited to dry skin, dark skin, and coarse pores.

  • Chronic skin inflammation, pigmentation, erythema, etc.

  • Cooperate with the experimental requirements and be able to complete the scoreindependently。

Exclusion

Exclusion Criteria:

  • Pregnant or lactating women.

  • Suffering from psychological or mental illness.

  • Life is not regular, overeating.

  • Hypersensitive to hyaluronic acid, and has a scar constitution.

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: 35 kDa hyaluronan fragment HA35 injection
Phase:
Study Start date:
April 15, 2024
Estimated Completion Date:
May 31, 2024

Connect with a study center

  • Nahia Impex LLC

    Ulaanbaatar,
    Mongolia

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.